Intertek acquires US-based QTI

Published: 15-Jun-2007
Regulatory Research & Development Cleaning

UK's Intertek Group, a scientific services company, has acquired Quantitative Technologies Inc (QTI). QTI will operate in the Intertek pharmaceutical services group.


UK's Intertek Group, a scientific services company, has acquired Quantitative Technologies Inc (QTI). QTI will operate in the Intertek pharmaceutical services group.

QTI is a contract analytical research and development laboratory that specialises in the pre-market launch stages of the drug and product development life cycle. The firm is located in New Jersey, US, with approximately 60 staff and counts major global pharmaceutical companies among its clients.

The acquisition advances Intertek's strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry through the provision of state of the art analytical services.

Intertek's Mark Loughead said: 'QTI has an outstanding reputation in the industry and will further expand our ability to support the pharmaceutical and related sectors for outsourced r&d and testing expertise.'

John Conti-Ramsden, global director for Intertek pharmaceutical services, added: 'The acquisition of QTI further develops Intertek's US offering and global platform in the area of pharmaceutical services.'

  • Companies:
  • Intertek
See more

You may also like

Research & Development

Intertek researches formulation strategies to repurpose biologic drugs

Read more
Achieving improvements in safety, efficacy and convenience for patients by using inhalation as an administration route

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Intertek researches formulation strategies to repurpose biologic drugs

Achieving improvements in safety, efficacy and convenience for patients by using inhalation as an administration route
Regulatory

Intertek expands bioanalytical services in San Diego

Extra capacity and technologies will expedite bioanalytical studies for clients
Regulatory

Intertek expands lab operations in Manchester, UK

Opens new biologic medicine contract services laboratory to be used for the development of medicines such as monoclonal antibodies
Regulatory

Intertek to launch expansion for complex pharmaceutical stability studies at CPhI/ICSE Worldwide

Stability studies provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of factors such as temperature, humidity & light
Sustainability

Cafosa obtains Intertek WCA certification

The WCA provides a powerful, cost-effective solution for companies and facilities seeking to improve workplace conditions efficiently and in accordance with widely accepted industry standards and best practices
Regulatory

Testing conditions for Intertek as 2013 results move steadily forward

Growth of revenues of £2,184m (up 6.3%) and profits £343m (up 2.2%) masked some tough conditions in the chemicals and pharma division.
Regulatory

Intertek establishes European immunochemistry centre

Will support clinical and pre-clinical development of biologic medicines such as monoclonal antibodies, proteins and biosimilars
Subscribe now